Imbio PHA (4.0.0) vs SignalHF
AI Verdict
Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA if your primary need is rapid, AI-driven analysis of CT pulmonary angiogram (CTPA) scans to objectively measure cardiac structures. This tool is ideal for aiding in the diagnosis and risk stratification of conditions like pulmonary embolism and hypertension, providing automated measurements and ratios for critical decision-making.
View Imbio PHA (4.0.0) →Choose SignalHF if…
Choose SignalHF if your focus is on proactively managing chronic heart failure patients with cardiac implantable electronic devices (CIEDs) to prevent hospitalizations. This AI algorithm excels at predicting heart failure hospitalizations within 30 days by analyzing CIED data, enabling timely intervention and personalized care plans.
View SignalHF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Imbio PHA (4.0.0) | SignalHF |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). | SaaS |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
TieBoth tools demonstrate strong usability tailored to their specific clinical users. Imbio PHA seamlessly integrates with native DICOM tools and PACS, offering fully automated and effortless processing for radiologists. SignalHF provides a unified platform for cardiac implantable electronic device (CIED) data, coupled with AI-driven alert management and actionable insights for cardiologists.
Clinical Value
SignalHFWhile both offer significant clinical benefits, SignalHF's predictive capability to anticipate heart failure hospitalizations within 30 days enables proactive intervention and personalized care, aiming to reduce hospitalizations and improve long-term patient outcomes. Imbio PHA, conversely, aids in the diagnosis and risk stratification of acute conditions like pulmonary embolism and hypertension through automated cardiac measurements.
Pricing & Value
TieBoth Imbio PHA and SignalHF require direct contact for pricing information, with no public details specified. Without transparent pricing, it is impossible to conduct a head-to-head comparison of their respective value propositions.
Enterprise Readiness
Imbio PHA (4.0.0)Both tools are FDA-cleared, HIPAA compliant, and offer Business Associate Agreements (BAAs), indicating strong regulatory readiness. However, Imbio PHA provides more flexible deployment options, including Cloud, Enterprise (on-premise), or via partners, which caters to a broader range of enterprise IT infrastructures and security preferences compared to SignalHF's SaaS-only deployment.
Innovation
SignalHFSignalHF demonstrates greater innovation by leveraging an FDA-cleared AI algorithm to *predict* heart failure hospitalizations from multi-brand CIED data, enabling proactive patient management. This predictive capability for preventing future adverse events is a more advanced application of AI compared to Imbio PHA's automation of existing cardiac measurements from CTPA scans.
Support & Docs
Imbio PHA (4.0.0)Both products offer documentation, including user manuals and brochures. However, Imbio PHA explicitly highlights an 'efficient implementation workflow' that can get clients live in '2 weeks or less' with 'minimal effort'. This suggests a more robust and streamlined support process for initial setup and ongoing operation.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Imbio PHA (4.0.0) | SignalHF |
|---|---|---|
| Name | Imbio PHA (4.0.0) | SignalHF |
| Company | Imbio | Implicity |
| Primary Function | Measures cardiac structures from CTPA scans to assess right ventricular dilation and aid in diagnosis/risk stratification of pulmonary embolism and hypertension. | Predicts heart failure hospitalizations within 30 days by analyzing data from various cardiac implantable electronic devices. |
| Target Medical Specialties | Cardiology, Pulmonology, Radiology | Cardiology |
| Core AI Application | AI-powered medical image processing | AI algorithm for heart failure prediction |
| Data Source | CT pulmonary angiogram (CTPA) scans | Data from various cardiac implantable electronic devices (CIEDs) |
| Key Output/Prediction | Automated measurement of RV/LV and PA/Ao diameters and ratios; annotated DICOM images; PDF summary reports. | Predicts heart failure hospitalizations within 30 days; generates automatic alerts for care teams based on risk scores. |
| Compatibility/Integration | Integrates with native DICOM tools and workflows | Manufacturer-agnostic compatibility with various CIEDs |
Videos
Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and SignalHF.